Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics and/or immunomodulators
Esteban Rodríguez-Martinó, Rafael Medina-Prieto, Jorge Santana-Bagur, María Santé, Petraleigh Pantoja, Ana M. Espino, View ORCID ProfileCarlos A. Sariol, Esther A. Torres
doi: https://doi.org/10.1101/2021.09.11.21263211
Esteban Rodríguez-Martinó
1MD. Division of Gastroenterology, Department of Medicine, University of Puerto Rico School of Medicine, San Juan, Puerto Rico
Rafael Medina-Prieto
1MD. Division of Gastroenterology, Department of Medicine, University of Puerto Rico School of Medicine, San Juan, Puerto Rico
Jorge Santana-Bagur
2Division of Infectious Diseases, Department of Medicine, University of Puerto Rico School of Medicine, San Juan
María Santé
3Department of Pathology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico
Petraleigh Pantoja
4Unit of Comparative Medicine, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico
Ana M. Espino
5Department of Microbiology and Medical Zoology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico
Carlos A. Sariol
4Unit of Comparative Medicine, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico
5Department of Microbiology and Medical Zoology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico
6Department of Medicine, University of Puerto Rico School of Medicine, San Juan
Esther A. Torres
1MD. Division of Gastroenterology, Department of Medicine, University of Puerto Rico School of Medicine, San Juan, Puerto Rico
Data Availability
All data related to this work is available upon request
Posted September 15, 2021.
Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics and/or immunomodulators
Esteban Rodríguez-Martinó, Rafael Medina-Prieto, Jorge Santana-Bagur, María Santé, Petraleigh Pantoja, Ana M. Espino, Carlos A. Sariol, Esther A. Torres
medRxiv 2021.09.11.21263211; doi: https://doi.org/10.1101/2021.09.11.21263211
Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics and/or immunomodulators
Esteban Rodríguez-Martinó, Rafael Medina-Prieto, Jorge Santana-Bagur, María Santé, Petraleigh Pantoja, Ana M. Espino, Carlos A. Sariol, Esther A. Torres
medRxiv 2021.09.11.21263211; doi: https://doi.org/10.1101/2021.09.11.21263211
Subject Area
Subject Areas
- Addiction Medicine (375)
- Allergy and Immunology (690)
- Anesthesia (185)
- Cardiovascular Medicine (2771)
- Dermatology (237)
- Emergency Medicine (415)
- Epidemiology (12423)
- Forensic Medicine (10)
- Gastroenterology (786)
- Genetic and Genomic Medicine (4288)
- Geriatric Medicine (396)
- Health Economics (703)
- Health Informatics (2769)
- Health Policy (1025)
- Hematology (371)
- HIV/AIDS (882)
- Medical Education (405)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4065)
- Nursing (218)
- Nutrition (602)
- Oncology (2145)
- Ophthalmology (607)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (78)
- Pathology (479)
- Pediatrics (1151)
- Primary Care Research (471)
- Public and Global Health (6669)
- Radiology and Imaging (1457)
- Respiratory Medicine (888)
- Rheumatology (425)
- Sports Medicine (353)
- Surgery (467)
- Toxicology (57)
- Transplantation (194)
- Urology (171)